Log-in
Sign-up
Webcast
Clinical Trials
Webcast
Clinical Trials
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
Active, not recruiting
NCT04668144
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
77
Enrollment(s)
1
Study location(s)
Interventional (Phase IV)
Coronary Artery Disease
Acute Coronary Syndrome
Completed
NCT03551743
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)
28
Enrollment(s)
0
Study location(s)
Interventional (Phase II)
Healthy Volunteers
연구종결
KCT0003380
비판막성 심방세동에 의한 급성 허혈성 뇌졸중 환자에서 조기 에독사반 투여의 효과 및 안전성 평가를 위한 무작위배정, 평행 대조, 다시관 예비 임상시험
68
Enrollment(s)
1
Study location(s)
중재연구 (None)
Terminated
NCT04606563
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
341
Enrollment(s)
13
Study location(s)
Interventional (Phase III)
Covid19
SARS-CoV Infection
Enrolling by invitation
NCT04284657
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
30
Enrollment(s)
1
Study location(s)
Interventional (Phase II)
Autosomal Dominant Polycystic Kidney Disease
Active, not recruiting
NCT04594915
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey
1,053
Enrollment(s)
45
Study location(s)
Observational
Atrial Fibrillation
Not yet recruiting
NCT05723510
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
76
Enrollment(s)
0
Study location(s)
Interventional (Phase I)
Healthy
Active, not recruiting
NCT03529110
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
524
Enrollment(s)
164
Study location(s)
Interventional (Phase III)
Breast Cancer
31
32
33
34
35